Liu Runping, Li Yajing, Zheng Qi, Ding Mingning, Zhou Huiping, Li Xiaojiaoyang
School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102400, China.
School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102400, China.
Acta Pharm Sin B. 2024 Mar;14(3):1009-1029. doi: 10.1016/j.apsb.2023.10.023. Epub 2023 Nov 4.
Liver fibrosis, characterized by scar tissue formation, can ultimately result in liver failure. It's a major cause of morbidity and mortality globally, often associated with chronic liver diseases like hepatitis or alcoholic and non-alcoholic fatty liver diseases. However, current treatment options are limited, highlighting the urgent need for the development of new therapies. As a reversible regulatory mechanism, epigenetic modification is implicated in many biological processes, including liver fibrosis. Exploring the epigenetic mechanisms involved in liver fibrosis could provide valuable insights into developing new treatments for chronic liver diseases, although the current evidence is still controversial. This review provides a comprehensive summary of the regulatory mechanisms and critical targets of epigenetic modifications, including DNA methylation, histone modification, and RNA modification, in liver fibrotic diseases. The potential cooperation of different epigenetic modifications in promoting fibrogenesis was also highlighted. Finally, available agonists or inhibitors regulating these epigenetic mechanisms and their potential application in preventing liver fibrosis were discussed. In summary, elucidating specific druggable epigenetic targets and developing more selective and specific candidate medicines may represent a promising approach with bright prospects for the treatment of chronic liver diseases.
肝纤维化以瘢痕组织形成为特征,最终可导致肝衰竭。它是全球发病和死亡的主要原因,常与慢性肝病如肝炎、酒精性和非酒精性脂肪性肝病相关。然而,目前的治疗选择有限,凸显了开发新疗法的迫切需求。作为一种可逆的调节机制,表观遗传修饰参与了包括肝纤维化在内的许多生物学过程。尽管目前的证据仍存在争议,但探索肝纤维化中涉及的表观遗传机制可为开发慢性肝病的新治疗方法提供有价值的见解。本综述全面总结了肝纤维化疾病中表观遗传修饰的调节机制和关键靶点,包括DNA甲基化、组蛋白修饰和RNA修饰。还强调了不同表观遗传修饰在促进纤维化形成中的潜在协同作用。最后,讨论了调节这些表观遗传机制的可用激动剂或抑制剂及其在预防肝纤维化中的潜在应用。总之,阐明特定的可成药表观遗传靶点并开发更具选择性和特异性的候选药物可能是治疗慢性肝病的一种有前景的方法,前景光明。